Author:
Chen Nan-Yan,Chen Kang-Hua,Wang Yi-Wen,Tsai Hsiu-Hsin,Lee Wei-Chen,Weng Li-Chueh
Abstract
Abstract
Background
Trans-hepatic arterial chemoembolization (TACE) is a treatment option for liver cancer patients. It can prolong patients’ survival but can also cause symptom distress. Symptom distress (SDs) can directly impact quality of life (QOL) and may indirectly influence QOL by lessening hope. In this study, we wanted to explore the mediating effect of hope on the relationship between SDs and QOL among patients with liver cancer receiving TACE.
Methods
A cross-sectional study was conducted from December 20, 2017, to August 6, 2018, at a gastroenterology ward of a medical center. The participants were 92 liver cancer patients (69.6% male, mean age 67.8) who were admitted for TACE treatment. Information on SDs, hope, and QOL was collected by questionnaire on discharge day. Hayes’ PROCESS model was used to test the mediating effect of hope on the relationship between SDs and QOL.
Results
The mean score and standard deviation (SD) of SDs, hope, and QOL were 32.08 (SD = 6.22), 27.09 (SD = 3.51), and 55.16 (SD = 17.33), respectively. SDs negatively impacts quality of life. The total effect of SDs on QOL was − 1.41 (95% confidence interval [CI]: − 1.96, − 0.86). The indirect effect via the mediation of hope was − 0.95 (95% CI: − 1.7, − 0.45). Hope partially mediated the effect of SDs on QOL.
Conclusion
SDs after TACE is vital; it directly reduces a patient’s overall QOL and can indirectly hinder it by reducing the patient’s hope. In addition to symptom management, interventions that help patients maintain their hope are key to improving QOL among patients receiving TACE.
Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,General Medicine
Reference34 articles.
1. Fernandes ESM, Rodrigues PD, Álvares-da-Silva MR, Scaffaro LA, Farenzena M, Teixeira UF, Waechter FL. Treatment strategies for locally advanced hepatocellular carcinoma. Transl Gastroenterol Hepatol. 2019;4:12. https://doi.org/10.21037/tgh.2019.01.02.
2. Li L, Chan SL, Mo F, Hui EP, Koh J, Chan AKC, et al. Correlations of health-related quality of life with serum inflammatory indicators IL-8 and mIBI in patients with hepatocellular carcinoma. Cancer Manag Res. 2019;11:2719–27. https://doi.org/10.2147/CMAR.S178482.
3. Ministry of Health and Welfare [Internet]. The main cause of death in 2019 [cited 2021 Feb 10]. Available from: http://www.mohw.gov.tw/cht/DOS/Statistic.aspx? (Original work published in Chinese).
4. Philips CA, Rajesh S, Nair DC, Ahamed R, Abduljaleel JK, Augustine P. Hepatocellular carcinoma in 2021: an exhaustive update. Cureus. 2021, 13(11). https://doi.org/10.7759/cureus.19274.
5. Li L, Yeo W. Value of quality of life analysis in liver cancer: a clinician’s perspective. World J Hepatol. 2017;9(20):867–83. https://doi.org/10.4254/wjh.v9.i20.867.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献